Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2014 1
2015 1
2016 1
2017 1
2018 2
2019 4
2020 9
2021 17
2022 11
2023 8
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
Spinou A, Hererro-Cortina B, Aliberti S, Goeminne PC, Polverino E, Dimakou K, Haworth CS, Loebinger MR, De Soyza A, Vendrell M, Burgel PR, McDonnell M, Sutharsan S, Skrgat S, Maiz-Carro L, Sibila O, Stolz D, Kauppi P, Bossios A, Hill AT, Clifton I, Crichton ML, Walker P, Menendez R, Borecki S, Obradovic D, Nowinski A, Amorim A, Torres A, Lorent N, Welte T, Blasi F, Makek MJ, Shteinberg M, Boersma W, Elborn JS, Chalmers JD, Ringshausen FC; EMBARC Registry Collaborators. Spinou A, et al. Among authors: sutharsan s. Eur Respir J. 2024 Apr 12:2301689. doi: 10.1183/13993003.01689-2023. Online ahead of print. Eur Respir J. 2024. PMID: 38609097
Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.
Gruber W, Stehling F, Blosch C, Dillenhoefer S, Olivier M, Brinkmann F, Koerner-Rettberg C, Sutharsan S, Mellies U, Taube C, Welsner M. Gruber W, et al. Among authors: sutharsan s. Front Sports Act Living. 2024 Feb 23;6:1284878. doi: 10.3389/fspor.2024.1284878. eCollection 2024. Front Sports Act Living. 2024. PMID: 38463712 Free PMC article.
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Schwarz C, Bend J, Hebestreit H, Hogardt M, Hügel C, Illing S, Mainz JG, Rietschel E, Schmidt S, Schulte-Hubbert B, Sitter H, Wielpütz MO, Hammermann J, Baumann I, Brunsmann F, Dieninghoff D, Eber E, Ellemunter H, Eschenhagen P, Evers C, Gruber S, Koitschev A, Ley-Zaporozhan J, Düesberg U, Mentzel HJ, Nüßlein T, Ringshausen FC, Sedlacek L, Smaczny C, Sommerburg O, Sutharsan S, Vonberg RP, Weber AK, Zerlik J. Schwarz C, et al. Among authors: sutharsan s. Pneumologie. 2024 Feb 29. doi: 10.1055/a-2278-6685. Online ahead of print. Pneumologie. 2024. PMID: 38423036 German. No abstract available.
[CF Lung Disease - a German S3 Guideline: Pseudomonas aeruginosa].
Schwarz C, Bend J, Hebestreit H, Hogardt M, Hügel C, Illing S, Mainz JG, Rietschel E, Schmidt S, Schulte-Hubbert B, Sitter H, Wielpütz MO, Hammermann J, Baumann I, Brunsmann F, Dieninghoff D, Eber E, Ellemunter H, Eschenhagen P, Evers C, Gruber S, Koitschev A, Ley-Zaporozhan J, Düesberg U, Mentzel HJ, Nüßlein T, Ringshausen FC, Sedlacek L, Smaczny C, Sommerburg O, Sutharsan S, Vonberg RP, Weber AK, Zerlik J. Schwarz C, et al. Among authors: sutharsan s. Pneumologie. 2024 Feb 13. doi: 10.1055/a-2182-1907. Online ahead of print. Pneumologie. 2024. PMID: 38350639 Free article. German.
Morphological chest CT changes in cystic fibrosis and massive hemoptysis.
Dohna M, Kühl H, Sutharsan S, Bruns N, Vo Chieu VD, Hellms S, Kornemann N, Montag MJ. Dohna M, et al. Among authors: sutharsan s. Radiologie (Heidelb). 2024 Feb 7. doi: 10.1007/s00117-024-01266-4. Online ahead of print. Radiologie (Heidelb). 2024. PMID: 38326635 English.
Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy.
Gruber W, Welsner M, Blosch C, Dillenhoefer S, Olivier M, Brinkmann F, Koerner-Rettberg C, Sutharsan S, Mellies U, Taube C, Stehling F. Gruber W, et al. Among authors: sutharsan s. Healthcare (Basel). 2023 Oct 31;11(21):2873. doi: 10.3390/healthcare11212873. Healthcare (Basel). 2023. PMID: 37958017 Free PMC article.
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.
Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, Ellemunter H, Dittrich AM, Smaczny C, Eickmeier O, Kappler M, Schwarz C, Sieber S, Naehrig S, Naehrlich L; German CF Registry of the Mukoviszidose e.V. and participating CF sites. Sutharsan S, et al. Lancet Reg Health Eur. 2023 Jul 28;32:100690. doi: 10.1016/j.lanepe.2023.100690. eCollection 2023 Sep. Lancet Reg Health Eur. 2023. PMID: 37554663 Free PMC article.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Free article. Clinical Trial.
Bronchial artery diameter in massive hemoptysis in cystic fibrosis.
Dohna M, Kühl H, Sutharsan S, Dohna-Schwake C, Vo Chieu VD, Hellms S, Kornemann N, Renz DM, Montag MJ. Dohna M, et al. Among authors: sutharsan s. BMC Pulm Med. 2022 Nov 17;22(1):424. doi: 10.1186/s12890-022-02233-2. BMC Pulm Med. 2022. PMID: 36397043 Free PMC article.
Barriers for Sports and Exercise Participation and Corresponding Barrier Management in Cystic Fibrosis.
Dillenhoefer S, Stehling F, Welsner M, Schlegtendal A, Sutharsan S, Olivier M, Taube C, Mellies U, Koerner-Rettberg C, Brinkmann F, Gruber W. Dillenhoefer S, et al. Among authors: sutharsan s. Int J Environ Res Public Health. 2022 Oct 13;19(20):13150. doi: 10.3390/ijerph192013150. Int J Environ Res Public Health. 2022. PMID: 36293733 Free PMC article.
Psychometric Validation of the German Translation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B)-Data from the German Bronchiectasis Registry PROGNOSIS.
Quellhorst L, Barten-Neiner G, de Roux A, Diel R, Mertsch P, Pink I, Rademacher J, Sutharsan S, Welte T, Zurawski A, Ringshausen FC, On Behalf Of The Prognosis Study Group. Quellhorst L, et al. Among authors: sutharsan s. J Clin Med. 2022 Jan 15;11(2):441. doi: 10.3390/jcm11020441. J Clin Med. 2022. PMID: 35054135 Free PMC article.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.
Elborn JS, Konstan MW, Taylor-Cousar JL, Fajac I, Horsley A, Sutharsan S, Aaron SD, Daines CL, Uluer A, Downey DG, Lucidi VV, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM; EMPIRE-CF study group. Elborn JS, et al. Among authors: sutharsan s. J Cyst Fibros. 2021 Nov;20(6):1026-1034. doi: 10.1016/j.jcf.2021.08.007. Epub 2021 Sep 17. J Cyst Fibros. 2021. PMID: 34538755 Free PMC article. Clinical Trial.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. Among authors: sutharsan s. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.
Coil embolisation for massive haemoptysis in cystic fibrosis.
Dohna M, Renz DM, Stehling F, Dohna-Schwake C, Sutharsan S, Neurohr C, Wirtz H, Eickmeier O, Grosse-Onnebrink J, Sauerbrey A, Soditt V, Poplawska K, Wacker F, Montag MJ. Dohna M, et al. Among authors: sutharsan s. BMJ Open Respir Res. 2021 Aug;8(1):e000985. doi: 10.1136/bmjresp-2021-000985. BMJ Open Respir Res. 2021. PMID: 34385150 Free PMC article.
ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19.
Möhlendick B, Schönfelder K, Breuckmann K, Elsner C, Babel N, Balfanz P, Dahl E, Dreher M, Fistera D, Herbstreit F, Hölzer B, Koch M, Kohnle M, Marx N, Risse J, Schmidt K, Skrzypczyk S, Sutharsan S, Taube C, Westhoff TH, Jöckel KH, Dittmer U, Siffert W, Kribben A. Möhlendick B, et al. Among authors: sutharsan s. Pharmacogenet Genomics. 2021 Oct 1;31(8):165-171. doi: 10.1097/FPC.0000000000000436. Pharmacogenet Genomics. 2021. PMID: 34001841 Free PMC article.
Transmembrane serine protease 2 Polymorphisms and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection: A German Case-Control Study.
Schönfelder K, Breuckmann K, Elsner C, Dittmer U, Fistera D, Herbstreit F, Risse J, Schmidt K, Sutharsan S, Taube C, Jöckel KH, Siffert W, Kribben A, Möhlendick B. Schönfelder K, et al. Among authors: sutharsan s. Front Genet. 2021 Apr 21;12:667231. doi: 10.3389/fgene.2021.667231. eCollection 2021. Front Genet. 2021. PMID: 33968142 Free PMC article.
The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19.
Schönfelder K, Breuckmann K, Elsner C, Dittmer U, Fistera D, Herbstreit F, Risse J, Schmidt K, Sutharsan S, Taube C, Jöckel KH, Siffert W, Kribben A, Möhlendick B. Schönfelder K, et al. Among authors: sutharsan s. Cytokine. 2021 Jun;142:155492. doi: 10.1016/j.cyto.2021.155492. Epub 2021 Mar 6. Cytokine. 2021. PMID: 33711707 Free PMC article. Clinical Trial.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
McKone EF, DiMango EA, Sutharsan S, Barto TL, Campbell D, Ahluwalia N, Higgins M, Owen CA, Tullis E. McKone EF, et al. Among authors: sutharsan s. J Cyst Fibros. 2021 Mar;20(2):234-242. doi: 10.1016/j.jcf.2020.11.003. Epub 2020 Dec 16. J Cyst Fibros. 2021. PMID: 33339768 Free article. Clinical Trial.
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL; WILLOW Investigators. Chalmers JD, et al. N Engl J Med. 2020 Nov 26;383(22):2127-2137. doi: 10.1056/NEJMoa2021713. Epub 2020 Sep 7. N Engl J Med. 2020. PMID: 32897034 Clinical Trial.
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
Schwarz C, Sutharsan S, Epaud R, Klingsberg RC, Fischer R, Rowe SM, Audhya PK, Ahluwalia N, You X, Ferro TJ, Duncan ME, Bruinsma BG. Schwarz C, et al. Among authors: sutharsan s. J Cyst Fibros. 2021 Mar;20(2):228-233. doi: 10.1016/j.jcf.2020.06.001. Epub 2020 Jun 23. J Cyst Fibros. 2021. PMID: 32586736 Free PMC article. Clinical Trial.
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).
van Koningsbruggen-Rietschel S, Conrath K, Fischer R, Sutharsan S, Kempa A, Gleiber W, Schwarz C, Hector A, Van Osselaer N, Pano A, Corveleyn S, Bwirire D, Santermans E, Muller K, Bellaire S, Van de Steen O. van Koningsbruggen-Rietschel S, et al. Among authors: sutharsan s. J Cyst Fibros. 2020 Mar;19(2):292-298. doi: 10.1016/j.jcf.2019.09.006. Epub 2019 Oct 5. J Cyst Fibros. 2020. PMID: 31594690 Free article. Clinical Trial.
SPEF2- and HYDIN-Mutant Cilia Lack the Central Pair-associated Protein SPEF2, Aiding Primary Ciliary Dyskinesia Diagnostics.
Cindrić S, Dougherty GW, Olbrich H, Hjeij R, Loges NT, Amirav I, Philipsen MC, Marthin JK, Nielsen KG, Sutharsan S, Raidt J, Werner C, Pennekamp P, Dworniczak B, Omran H. Cindrić S, et al. Among authors: sutharsan s. Am J Respir Cell Mol Biol. 2020 Mar;62(3):382-396. doi: 10.1165/rcmb.2019-0086OC. Am J Respir Cell Mol Biol. 2020. PMID: 31545650
Prevalence and characterization of azole-resistant Aspergillus fumigatus in patients with cystic fibrosis: a prospective multicentre study in Germany.
Seufert R, Sedlacek L, Kahl B, Hogardt M, Hamprecht A, Haase G, Gunzer F, Haas A, Grauling-Halama S, MacKenzie CR, Essig A, Stehling F, Sutharsan S, Dittmer S, Killengray D, Schmidt D, Eskandarian N, Steinmann E, Buer J, Hagen F, Meis JF, Rath PM, Steinmann J. Seufert R, et al. Among authors: sutharsan s. J Antimicrob Chemother. 2018 Aug 1;73(8):2047-2053. doi: 10.1093/jac/dky147. J Antimicrob Chemother. 2018. PMID: 29684150
Invasive Pulmonary Fungal Infections in Cystic Fibrosis.
Schwarz C, Brandt C, Whitaker P, Sutharsan S, Skopnik H, Gartner S, Smazny C, Röhmel JF. Schwarz C, et al. Among authors: sutharsan s. Mycopathologia. 2018 Feb;183(1):33-43. doi: 10.1007/s11046-017-0199-4. Epub 2017 Sep 1. Mycopathologia. 2018. PMID: 28864921
Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.
Junge S, Görlich D, den Reijer M, Wiedemann B, Tümmler B, Ellemunter H, Dübbers A, Küster P, Ballmann M, Koerner-Rettberg C, Große-Onnebrink J, Heuer E, Sextro W, Mainz JG, Hammermann J, Riethmüller J, Graepler-Mainka U, Staab D, Wollschläger B, Szczepanski R, Schuster A, Tegtmeyer FK, Sutharsan S, Wald A, Nofer JR, van Wamel W, Becker K, Peters G, Kahl BC. Junge S, et al. Among authors: sutharsan s. PLoS One. 2016 Nov 18;11(11):e0166220. doi: 10.1371/journal.pone.0166220. eCollection 2016. PLoS One. 2016. PMID: 27861524 Free PMC article.
Practical guidelines: lung transplantation in patients with cystic fibrosis.
Hirche TO, Knoop C, Hebestreit H, Shimmin D, Solé A, Elborn JS, Ellemunter H, Aurora P, Hogardt M, Wagner TO; ECORN-CF Study Group. Hirche TO, et al. Pulm Med. 2014;2014:621342. doi: 10.1155/2014/621342. Epub 2014 Mar 30. Pulm Med. 2014. PMID: 24800072 Free PMC article.